362 POSTER A phase 2 trial of AP23573, an mTOR inhibitor, in patients (pts) with taxane-resistant androgen-independent prostate cancer (AIPC)

✍ Scribed by M.E. Gross; R.J. Amato; M. Mushtaq; G. Wilding; G. Bubley

• Book ID: 118623990
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 57 KB
• Volume: 4
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(06)70367-6